Condition: Phenylketonuria · Sponsor: Agios Pharmaceuticals, Inc.
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
This description comes directly from the study's public registry record.
Agios Medical Affairs · 833-228-8474 · medinfo@agios.com
Always discuss trial participation with your own doctor first.
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| UPMC Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Texas Southwestern Medical Center (UTSW) | Dallas, Texas, United States | Recruiting |
| Centrum Wsparcia Badań Klinicznych Pomorskiego Uniwersytetu Medycznego w Szczecinie | Szczecin, West Pomeranian Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07241234